他汀类药物治疗可能会增加糖尿病的风险;关于他汀类药物如何影响葡萄糖调节和血糖控制的数据不足,他汀类药物对与碳水化合物代谢相关的肝酶的影响尚未得到充分研究。因此,我们的目的是比较他汀类药物衍生物的作用,普伐他汀,和瑞舒伐他汀,关于实验性糖尿病大鼠模型中碳水化合物代谢的研究。使用雌性Wistar白化病大鼠,并通过腹膜内注射链脲佐菌素诱导糖尿病。此后,通过口服管饲法向糖尿病大鼠施用10和20mgkg-1天-1剂量的普伐他汀和瑞舒伐他汀。实验结束时,身体肿块,空腹血糖水平,血清胰岛素,胰岛素抵抗(HOMA-IR),肝糖原,并测定与碳水化合物代谢相关的肝酶。两种剂量的普伐他汀都显着增加了糖尿病大鼠的体重,然而,瑞舒伐他汀,特别是在20mgkg-1day-1的剂量下,体重显着降低。普伐他汀,特别是在20mgkg-1day-1的剂量下,导致肝糖原合酶和葡萄糖6-磷酸脱氢酶水平显着增加,但糖原磷酸化酶水平显着降低,乳酸脱氢酶,和葡萄糖-6-磷酸酶。因此,普伐他汀部分改善了糖尿病引起的肝酶的不良变化,特别是在20mgkg-1day-1的剂量下,降低了空腹血糖水平并增加了肝糖原含量。然而,瑞舒伐他汀,特别是在20mgkg-1day-1的剂量下,显着降低了肝糖原合成酶和丙酮酸激酶的水平,但是增加了糖尿病大鼠的糖原磷酸化酶水平。瑞舒伐他汀,20mgkg-1天-1剂量,导致糖尿病大鼠的体重和肝糖原含量显着下降。可以得出结论普伐他汀,特别是在20mgkg-1day-1的剂量下,通过调节碳水化合物代谢更有效地改善糖尿病的负面影响。
Statin treatment may increase the risk of diabetes; there is insufficient data on how statins affect glucose regulation and glycemic control and the effects of statins on liver enzymes related to carbohydrate metabolism have not been fully studied. Therefore, we aimed to compare the effects of the statin derivatives, pravastatin, and rosuvastatin, on carbohydrate metabolism in an experimental diabetic rat model. Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin. Thereafter, 10 and 20 mg kg-1 day-1 doses of both pravastatin and rosuvastatin were administered by oral gavage to the diabetic rats for 8 weeks. At the end of the experiment, body masses, the levels of fasting blood glucose, serum insulin, insulin resistance (HOMA-IR), liver glycogen, and liver enzymes related to carbohydrate metabolism were measured. Both doses of pravastatin significantly in creased the body mass in diabetic rats, however, rosuvastatin, especially at the dose of 20 mg kg-1 day-1 reduced the body mass signi ficantly. Pravastatin, especially at a dose of 20 mg kg-1 day-1, caused significant increases in liver glycogen synthase and glucose 6-phosphate dehydrogenase levels but significant decreases in the levels of glycogen phosphorylase, lactate dehydrogenase, and glucose-6-phosphatase. Hence, pravastatin partially ameliorated the adverse changes in liver enzymes caused by diabetes and, especially at the dose of 20 mg kg-1 day-1, reduced the fasting blood glucose level and increased the liver glycogen content. However, rosuvastatin, especially at the dose of 20 mg kg-1 day-1, significantly reduced the liver glycogen synthase and pyruvate kinase levels, but increased the glycogen phosphorylase level in diabetic rats. Rosuvastatin, 20 mg kg-1 day-1 dose, caused significant decreases in the body mass and the liver glycogen content of diabetic rats. It can be concluded that pravastatin, especially at the dose of 20 mg kg-1 day-1 is more effective in ameliorating the negative effects of diabetes by modulating carbohydrate metabolism.